BackBetter Therapeutics Overview

Better Therapeutics Operating Income

Latest operating income for MCAD: $-30M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-5341000.00
↓ 51.43% YoY

As of Sep 30, 2023

Annual Operating Income (TTM)

$-29613000.00
↓ 29.57% YoY

Trailing 12 months ending Sep 30, 2023

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Better Therapeutics (MCAD) FAQ

As of the most recent data (September 2023), MCAD shows a operating income of $-30M. That compares with $-42M in the prior-year period — up 29.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MCAD's operating income is now $-30M (was $-42M) — a 29.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Better Therapeutics is outperforming or lagging.

Tracking MCAD's operating income over time shows whether Better Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-30M That compares with $-42M in the prior-year period — up 29.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Better Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-30M) with ownership activity and broader fundamentals.